Medidata has introduced its latest offering, the Medidata Protocol Optimization, as part of the Medidata Study Experience available on their platform. This new solution is being showcased at the American Society of Clinical Oncology (ASCO) 2025 conference, scheduled for May 30 to June 3, 2025, in Chicago.
Designed to revolutionize trial design and execution, Medidata Protocol Optimization utilizes AI-driven predictive modeling, digital protocols, and comprehensive aggregated data. By simulating trial performance, it allows for early prediction of patient burden, site performance, and associated costs before the first patient is even involved. This foresight helps research teams anticipate potential hurdles, significantly reducing the need for costly amendments and enrollment delays. Ultimately, this technology leads to more efficient and cost-effective trials.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 3 analysts, the average target price for Dassault Systemes SE (DASTY, Financial) is $38.95 with a high estimate of $45.84 and a low estimate of $26.91. The average target implies an upside of 3.14% from the current price of $37.77. More detailed estimate data can be found on the Dassault Systemes SE (DASTY) Forecast page.
Based on the consensus recommendation from 2 brokerage firms, Dassault Systemes SE's (DASTY, Financial) average brokerage recommendation is currently 3.0, indicating "Hold" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Dassault Systemes SE (DASTY, Financial) in one year is $50.51, suggesting a upside of 33.73% from the current price of $37.77. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Dassault Systemes SE (DASTY) Summary page.
